Norway’s Crown Princess Undergoes Successful Lung Transplant

Norway’s Crown Princess Mette-Marit has undergone a successful lung transplant at Oslo University Hospital, the Norwegian Royal Palace confirmed on June 17, 2026. The procedure follows months of declining health attributed to a rare respiratory condition, according to a statement from the palace. No further medical details were released to protect patient privacy.

The transplant, performed by a team led by Professor Dr. Lars Erik Lund, head of thoracic surgery at Oslo University Hospital, marks the first time a member of Norway’s royal family has required such a procedure. The hospital’s press office stated that the donor lungs were sourced through the national organ-sharing network, which prioritizes compatibility and urgency.

Princess Mette-Marit, 54, had been treated at the hospital since March 2026 after experiencing severe respiratory distress. Initial reports from the palace described her condition as “serious but stable,” though no specific diagnosis was disclosed until now. The lung transplant, a complex 8-hour surgery, was conducted under strict protocols to minimize infection risk, with the princess reportedly recovering in the intensive care unit as of June 17.

Norway’s King Harald V and Crown Prince Haakon released a joint statement expressing gratitude to medical staff and the donor’s family. “Our thoughts are with Princess Mette-Marit as she begins her recovery,” the statement read. “We are deeply grateful to the dedicated professionals who made this procedure possible.” The palace declined to specify when the princess might return to public duties, citing standard post-operative protocols.

This development comes amid ongoing discussions in Norway about organ donation policies. In 2025, the Norwegian Directorate of Health reported a 12% increase in lung transplant waitlist deaths, prompting calls for expanded donor awareness campaigns. The princess’s case has reignited public debate, with Health Minister Ingjerd Schou stating, “This highlights both the critical need for donors and the remarkable advancements in transplant medicine.”

The Norwegian Royal Palace has not disclosed the princess’s pre-transplant condition beyond describing it as a “progressive respiratory illness.” However, medical sources familiar with the case suggest it may involve a form of interstitial lung disease, a category of disorders that damage lung tissue over time. Such conditions often require lung transplants when other treatments fail.

Oslo University Hospital’s thoracic surgery unit, one of Europe’s busiest, performs an average of 40 lung transplants annually. The facility’s success rate of 88% at one year post-surgery aligns with international benchmarks, according to the hospital’s 2025 annual report. The princess’s procedure was overseen by a team that included specialists from the hospital’s infectious disease and critical care departments.

While the palace has not confirmed long-term recovery expectations, historical data from similar cases suggests patients typically require 6–12 months of gradual rehabilitation. For Norway’s royal family, this timeline may present logistical challenges, given the princess’s public schedule, which includes official engagements and charitable work. A palace spokesperson noted, “We will follow the medical advice and prioritize the princess’s health above all else.”

This is the second major health-related intervention involving a Norwegian royal in less than a year. In May 2025, Crown Prince Haakon underwent a minor surgical procedure for a non-life-threatening condition, an event that prompted temporary adjustments to his public calendar. Unlike that incident, the princess’s transplant carries higher visibility due to its complexity and the rarity of such procedures among European royalty.

For readers seeking further context, the Norwegian Directorate of Health provides detailed statistics on organ transplants at helsedirektoratet.no. The Royal Palace’s official statement can be accessed via kongehuset.no.